Peripheral blood stem cell mobilization with pegfilgrastim in children with solid malignancies

Summary. In studies conducted in adult patients with neoplasia proven that prolonged conjugated with polyethylene glycol form of recombinant human granulocyte colony-stimulating factor — pegfilgrastim, is as effective as filgrastim for the mobilization of CD34 stem cells. Currently, only a small number of published observations on small groups of patients, describing pegfilgrastim ability to mobilize CD34 stem cells in children. Three groups of patients were analyzed. Group 1: 15 patients with Ewing’s sarcoma/PNET — primitive neuroectodermal tumor, neuroblastoma, teratoblastoma received filgrastim; Group 2: 10 patients with Ewing’s sarcoma/PNET, neuroblastoma, medulloblastoma, clear cell sarcoma. Group 3: 6 children with recurrent neoplasia (with Ewing’s sarcoma/PNET, neuroblastoma). Patients of groups 2 and 3 stimulated pegfilgrastim. One patient in group 3 was in need of additional stimulation of filgrastim. In groups 1–3, the average was conducted 1,5; 1,3 and 1,3 in terms peripheral stem cell collection 14,1; 12.9 and 19 days after chemotherapy, mobilization, to obtain on average 7,45; 7,95 and 3,35 x 106 CD34 stem cells/kg body weight. Single-dose pegfilgrastim to mobilize stem CD34 peripheral blood cells, a small group of patients has been achieved earlier peripheral stem cell collection, more CD34 cells/kg collected per procedure and less the procedures than daily administration filhrastym within 5–18 days. Pegfilgrastim effective to mobilize CD34 stem cells in the peripheral blood of children with newly diagnosed as malignant solid tumors, and in patients with recurrent disease.